Efmoroctocog alfa

Efmoroctocog alfa, sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A.^[5][6][7] Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc).^[5] It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line.^[5][6]

Efmoroctocog alfa

Clinical data
Trade names	Elocta, Eloctate
Other names	Antihemophilic Factor (Recombinant), FcFusion Protein
License data	EU EMA: by INN US DailyMed: Eloctate
Pregnancy category	AU: C[1]
Routes of administration	Intravenous
Drug class	Antihemorrhagic
ATC code	None
Legal status
Legal status	AU: Unscheduled[1][2][3] UK: POM (Prescription only)[4] US: ℞-only[5] EU: Rx-only[6]
Identifiers
CAS Number	1270012-79-7
DrugBank	DB11607
UNII	7PCM518YLR
KEGG	D10830 D10539
Chemical and physical data
Formula	C9736H14863N2591O2855S78
Molar mass	216390.96 g·mol−1

It was approved for medical use in the United States in June 2014,^[8] and for use in the European Union in November 2015.^[6]

Medical uses

In the United States, efmoroctocog alfa (Eloctate) is indicated for adults and children with Hemophilia A for (1) on-demand treatment and control of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.^[9][5]

In the European Union, efmoroctocog alfa (Elocta) is indicated for treatment and prophylaxis of bleeding in people with haemophilia A.^[6]